Regulatory Potential of Non-Coding RNAs Colocalized with Cardiomyopathy-Related Genes

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Non-coding RNAs (ncRNAs) play an important role in the regulation of the activity of genes essential for the development and function of the cardiovascular system. Intragenic ncRNAs have been shown to be coordinately regulated and/or expressed with their host genes, including ncRNAs resided within cardiomyopathy (CMP)-related genes. This review summarizes the results of CMP-related intragenic ncRNA studies in the function of the healthy heart and in the development of different forms of CMPs. CMP-related intragenic ncRNAs such as miRNAs (miR-1, miR-133a, miR-208a, miR-208b, miR-324, miR-490, miR-499a) and long ncRNAs (MHRT, TTN-AS1 and KCNQ1OT1) are actively involved in research. It has been established that the level of these of ncRNAs in myocardium is characterized by developmental-stage-specific dynamics, gender-specific and chamber-specific patterns. These ncRNAs exhibit differential expression in myocardium/serum of humans and model animals under the influence of exogenous and endogenous factors. The expression levels of these ncRNAs in the myocardium/serum is associated with clinical features during the development and progression of CMPs. The change in the level of ncRNAs preceding clinical manifestation of CMPs have been reported. The possibility to arrest the development of CMPs and even the restoration of the normal phenotype by controlling the levels of these regulatory molecules indicate their involvement in the pathogenesis of the disease. miRNAs and long ncRNAs, whose genes resided within CMP-related genes, are involved in various metabolic processes that are important for the heart function, including their involvement in epigenetic processes.

About the authors

A. N. Kucher

Research Institute of Medical Genetics, Tomsk National Research Medical Center
of the Russian Academy of Sciences

Email: maria.nazarenko@medgenetics.ru
Russia, 634050, Tomsk

M. S. Nazarenko

Research Institute of Medical Genetics, Tomsk National Research Medical Center
of the Russian Academy of Sciences

Author for correspondence.
Email: maria.nazarenko@medgenetics.ru
Russia, 634050, Tomsk

References

  1. Zhou H., Wang B., Yang Y.X. et al. Long noncoding RNAs in pathological cardiac remodeling: A review of the update literature // Biomed. Res. Int. 2019. V. 2019. P. 7159592. https://doi.org/10.1155/2019/7159592
  2. Mushtaq I., Ishtiaq A., Ali T. et al. An overview of non-coding RNAs and cardiovascular system // Adv. Exp. Med. Biol. 2020. V. 1229. P. 3–45. https://doi.org/10.1007/978-981-15-1671-9_1
  3. Tang Y., Bao J., Hu J. et al. Circular RNA in cardiovascular disease: expression, mechanisms and clinical prospects // J. Cell. Mol. Med. 2021. V. 25. № 4. P. 1817–1824. https://doi.org/10.1111/jcmm.16203
  4. Qin X., Huang L., Chen S. et al. Multi-factor regulatory network and different clusters in hypertrophic obstructive cardiomyopathy // BMC Med. Genomics. 2021. V. 14. № 1. P. 199. https://doi.org/10.1186/s12920-021-01036-4
  5. Chiti E., Paolo M.D., Turillazzi E., Rocchi A. MicroRNAs in hypertrophic, arrhythmogenic and dilated cardiomyopathy // Diagnostics (Basel). 2021. V. 11. № 9. P. 1720. https://doi.org/10.3390/diagnostics11091720
  6. Cao M., Luo H., Li D. et al. Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases // Int. J. Cardiol. 2022. V. 353. P. 109–117. https://doi.org/10.1016/j.ijcard.2022.01.070
  7. Кучер А.Н., Назаренко М.С. Эпигенетика кардиомиопатий: модификации гистонов и метилирование ДНК // Генетика. 2023. Т. 59. № 3. С. 266–182.
  8. Li M., Duan L., Li Y., Liu B. Long noncoding RNA/circular noncoding RNA-miRNA-mRNA axes in cardiovascular diseases // Life Sci. 2019. V. 233. P. 116440. https://doi.org/10.1016/j.lfs.2019.04.066
  9. Shahzadi S.K., Naidoo N., Alsheikh-Ali A. et al. Reconnoitering the role of long-noncoding RNAs in hypertrophic cardiomyopathy: A descriptive review // Int. J. Mol. Sci. 2021. V. 22. № 17. P. 9378. https://doi.org/10.3390/ijms22179378
  10. Meder B., Haas J., Sedaghat-Hamedani F. et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure // Circulation. 2017. V. 136. № 16. P. 1528–1544. https://doi.org/10.1161/CIRCULATIONAHA.117. 027355
  11. Cheedipudi S.M., Matkovich S.J., Coarfa C. et al. Genomic reorganization of lamin-associated domains in cardiac myocytes is associated with differential gene expression and DNA methylation in human dilated cardiomyopathy // Circ. Res. 2019. V. 124. № 8. P. 1198–1213. https://doi.org/10.1161/CIRCRESAHA.118.314177
  12. Liu C.F., Abnousi A., Bazeley P. et al. Global analysis of histone modifications and long-range chromatin interactions revealed the differential cistrome changes and novel transcriptional players in human dilated cardiomyopathy // J. Mol. Cell. Cardiol. 2020. V. 145. P. 30–42. https://doi.org/10.1016/j.yjmcc.2020.06.001
  13. Pei J., Schuldt M., Nagyova E. et al. Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations // Clin. Epigenetics. 2021. V. 13. № 1. P. 61. https://doi.org/10.1186/s13148-021-01043-3
  14. Simple ClinVar [Electronic resource]. URL: https://simple-clinvar.broadinstitute.org/ Accessed 03.2022.
  15. Pérez-Palma E., Gramm M., Nürnberg P. et al. Simple ClinVar: An interactive web server to explore and retrieve gene and disease variants aggregated in ClinVar database // Nucl. Acids Res. 2019. V. 47. № W1. P. W99–W105. https://doi.org/10.1093/nar/gkz411
  16. ClinGen [Electronic resource]. URL: https://clinicalgenome.org/ Accessed 05.2022.
  17. miRBase: the microRNA database. [Electronic resource]. URL: https://www.mirbase.org/ Accessed 04.2022.
  18. RNAcentral: The non-coding RNA sequence database. [Electronic resource]. URL: https://rnacentral.org/ Accessed 04.2022.
  19. GeneCards®: The Human Gene Database [Electronic resource]. URL: https://www.genecards.org/ Accessed 04.2022.
  20. Khan M.A., Reckman Y.J., Aufiero S. et al. RBM20 Regulates circular RNA production from the titin gene // Circ. Res. 2016. V. 119. № 9. P. 996–1003. https://doi.org/10.1161/CIRCRESAHA.116.309568
  21. Dong K., He X., Su H. et al. Genomic analysis of circular RNAs in heart // BMC Med. Genomics. 2020. V. 13. № 1. P. 167. https://doi.org/10.1186/s12920-020-00817-7
  22. Gao J., Collyer J., Wang M. et al. Genetic dissection of hypertrophic cardiomyopathy with myocardial RNA-Seq // Int. J. Mol. Sci. 2020. V. 21. № 9. P. 3040. https://doi.org/10.3390/ijms21093040
  23. Hombach S., Kretz M. Non-coding RNAs: classification, biology and functioning // Adv. Exp. Med. Biol. 2016. V. 937. P. 3–17. https://doi.org/10.1007/978-3-319-42059-2_1
  24. Stavast C.J., Erkeland S.J. The non-canonical aspects of MicroRNAs: Many roads to gene regulation // Cells. 2019. V. 8. № 11. P. 1465. https://doi.org/10.3390/cells8111465
  25. Rao P.K., Toyama Y., Chiang H.R. et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure // Circ. Res. 2009. V. 105. № 6. P. 585–594. https://doi.org/10.1161/CIRCRESAHA.109.200451
  26. Yang L. Splicing noncoding RNAs from the inside out // Wiley Interdiscip. Rev. RNA. 2015. V. 6. № 6. P. 651–660. https://doi.org/10.1002/wrna.1307
  27. Jarroux J., Morillon A., Pinskaya M. History, discovery, and classification of lncRNAs // Adv. Exp. Med. Biol. 2017. V. 1008. P. 1–46. https://doi.org/10.1007/978-981-10-5203-3_1
  28. Luo S., Lu J.Y., Liu L. et al. Divergent lncRNAs regulate gene expression and lineage differentiation in pluripotent cells // Cell Stem Cell. 2016. V. 18. № 5. P. 637–652. https://doi.org/10.1016/j.stem.2016.01.024
  29. Barrett S.P., Salzman J. Circular RNAs: analysis, expression and potential functions // Development. 2016. V. 143. № 11. P. 1838–1847. https://doi.org/10.1242/dev.128074
  30. Liang D., Tatomer D.C., Luo Z. et al. The output of protein-coding genes shifts to circular RNAs when the pre-mRNA processing machinery is limiting // Mol. Cell. 2017. V. 68. № 5. P. 940–954.e3. https://doi.org/10.1016/j.molcel.2017.10.034
  31. Vo J.N., Cieslik M., Zhang Y. et al. The landscape of circular RNA in cancer // Cell. 2019. V. 176. № 4. P. 869–881.e13. https://doi.org/10.1016/j.cell.2018.12.021
  32. Kazimierczyk M., Kasprowicz M.K., Kasprzyk M.E., Wrzesinski J. Human long noncoding RNA interactome: detection, characterization and function // Int. J. Mol. Sci. 2020. V. 21. № 3. P. 1027. https://doi.org/10.3390/ijms21031027
  33. Yuan Y., Wang J., Chen Q. et al. Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling // Biochim. Biophys. Acta Mol. Basis Dis. 2019. V. 1865. № 6. P. 1421–1427. https://doi.org/10.1016/j.bbadis.2019.02.014
  34. Guo Q., Wang J., Sun R. et al. Comprehensive construction of a circular RNA-associated competing endogenous RNA network identified novel circular RNAs in hypertrophic cardiomyopathy by integrated analysis // Front. Genet. 2020. V. 11. P. 764. https://doi.org/10.3389/fgene.2020.00764
  35. Guo Q., Wang J., Sun R. et al. Identification of circulating hub long noncoding RNAs associated with hypertrophic cardiomyopathy using weighted correlation network analysis // Mol. Med. Rep. 2020. V. 22. № 6. P. 4637–4644. https://doi.org/10.3892/mmr.2020.11566
  36. Guo W., Schafer S., Greaser M.L. et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing // Nat. Med. 2012. V. 18. № 5. P. 766–773. https://doi.org/10.1038/nm.2693
  37. Gi W.T., Haas J., Sedaghat-Hamedani F. et al. Epigenetic regulation of alternative mRNA splicing in dilated cardiomyopathy // J. Clin. Med. 2020. V. 9. № 5. P. 1499. https://doi.org/10.3390/jcm9051499
  38. Oliveira-Carvalho V., Carvalho V.O., Bocchi E.A. The emerging role of miR-208a in the heart // DNA Cell. Biol. 2013. V. 32. № 1. P. 8–12. https://doi.org/10.1089/dna.2012.1787.0
  39. Han P., Li W., Lin C.H. et al. A long noncoding RNA protects the heart from pathological hypertrophy // Nature. 2014. V. 514. № 7520. P. 102–106. https://doi.org/10.1038/nature13596
  40. Zhao X., Wang Y., Sun X. The functions of microRNA-208 in the heart // Diabetes Res. Clin. Pract. 2020. V. 160. P. 108004. https://doi.org/10.1016/j.diabres.2020.108004
  41. Sun F., Yuan W., Wu H. et al. LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis // Exp. Biol. Med. (Maywood). 2020. V. 245. № 7. P. 620–630. https://doi.org/10.1177/1535370220908041
  42. Huang X.H., Li J.L., Li X.Y. et al. miR-208a in cardiac hypertrophy and remodeling // Front. Cardiovasc. Med. 2021. V. 8. P. 773314. https://doi.org/10.3389/fcvm.2021.773314
  43. van Rooij E., Quiat D., Johnson B.A. et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance // Dev. Cell. 2009. V. 17. № 5. P. 662–673. https://doi.org/10.1016/j.devcel.2009.10.013
  44. Korostowski L., Sedlak N., Engel N. The Kcnq1ot1 long non-coding RNA affects chromatin conformation and expression of Kcnq1, but does not regulate its imprinting in the developing heart // PLoS Genet. 2012. V. 8. № 9. P. e1002956. https://doi.org/10.1371/journal.pgen.1002956
  45. Wu C., Arora P. Long noncoding Mhrt RNA: Molecular crowbar unravel insights into heart failure treatment // Circ. Cardiovasc. Genet. 2015. V. 8. № 1. P. 213–215. https://doi.org/10.1161/CIRCGENETICS.115.001019
  46. Kakimoto Y., Tanaka M., Kamiguchi H. et al. MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart // Int. J. Cardiol. 2016. V. 211. P. 43–48. https://doi.org/10.1016/j.ijcard.2016.02.145
  47. Harikrishnan K.N., Okabe J., Mathiyalagan P. et al. Sex-based Mhrt methylation chromatinizes MeCP2 in the heart // iScience. 2019. V. 17. P. 288–301. https://doi.org/10.1016/j.isci.2019.06.031
  48. Iannolo G., Sciuto M.R., Cuscino N. et al. miRNA expression analysis in the human heart: Undifferentiated progenitors vs. bioptic tissues-implications for proliferation and ageing // J. Cell. Mol. Med. 2021. V. 25. № 18. P. 8687–8700. https://doi.org/10.1111/jcmm.16824
  49. Kim S.K., Bennett R., Ingles J. et al. Arrhythmia in cardiomyopathy: sex and gender differences // Curr. Heart Fail. Rep. 2021. V. 18. № 5. P. 274–283. https://doi.org/10.1007/s11897-021-00531-0
  50. Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction) // J. Mol. Cell. Cardiol. 2016. V. 94. P. 107–121. https://doi.org/10.1016/j.yjmcc.2016.03.015
  51. Callis T.E., Pandya K., Seok H.Y. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice // J. Clin. Invest. 2009. V. 119. № 9. P. 2772–2786. https://doi.org/10.1172/JCI36154
  52. Hupfeld J., Ernst M., Knyrim M. et al. miR-208b reduces the expression of Kcnj5 in a cardiomyocyte cell line // Biomedicines. 2021. V. 9. № 7. P. 719. https://doi.org/10.3390/biomedicines9070719
  53. Mathiyalagan P., Okabe J., Chang L. et al. The primary microRNA-208b interacts with Polycomb-group protein, Ezh2, to regulate gene expression in the heart // Nucl. Acids Res. 2014. V. 42. № 2. P. 790–803. https://doi.org/10.1093/nar/gkt896
  54. Zhou Q., Schötterl S., Backes D. et al. Inhibition of miR-208b improves cardiac function in titin-based dilated cardiomyopathy // Int. J. Cardiol. 2017. V. 230. P. 634–641. https://doi.org/10.1016/j.ijcard.2016.12.171
  55. Tsuji M., Kawasaki T., Matsuda T. et al. Sexual dimorphisms of mRNA and miRNA in human/murine heart disease // PLoS One. 2017. V. 12. № 7. P. e0177988. https://doi.org/10.1371/journal.pone.0177988
  56. Gioffré S., Ricci V., Vavassori C. et al. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity // Biomed. Pharmacother. 2019. V. 110. P. 1–8. https://doi.org/10.1016/j.biopha.2018.11.042
  57. Schultz B.M., Gallicio G.A., Cesaroni M. et al. Enhancers compete with a long non-coding RNA for regulation of the Kcnq1 domain // Nucl. Acids Res. 2015. V. 43. № 2. P. 745–759. https://doi.org/10.1093/nar/gku1324
  58. Terranova R., Yokobayashi S., Stadler M.B. et al. Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprinted repression in early mouse embryos // Dev. Cell. 2008. V. 15. № 5. P. 668–679. https://doi.org/10.1016/j.devcel.2008.08.015
  59. Halliday B.P., Gulati A., Ali A. et al. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy // Eur. J. Heart Fail. 2018. V. 20. № 10. P. 1392–1400. https://doi.org/10.1002/ejhf.1216
  60. Pelliccia F., Limongelli G., Autore C. et al. Sex-related differences in cardiomyopathies // Int. J. Cardiol. 2019. V. 286. P. 239–243. https://doi.org/10.1016/j.ijcard.2018.10.091
  61. De Bellis A., De Angelis G., Fabris E. et al. Gender-related differences in heart failure: beyond the “one-size-fits-all” paradigm // Heart Fail. Rev. 2020. V. 25. № 2. P. 245–255. https://doi.org/10.1007/s10741-019-09824-y
  62. Palacín M., Reguero J.R., Martín M. et al. Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations // Clin. Chem. 2011. V. 57. № 11. P. 1614–1616. https://doi.org/10.1373/clinchem.2011.168005
  63. Bagnall R.D., Tsoutsman T., Shephard R.E. et al. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure // PLoS One. 2012. V. 7. № 9. P. e44744. https://doi.org/10.1371/journal.pone.0044744
  64. Ferreira L.R., Frade A.F., Santos R.H. et al. MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in Chronic Chagas disease Cardiomyopathy // Int. J. Cardiol. 2014. V. 175. № 3. P. 409–417. https://doi.org/10.1016/j.ijcard.2014.05.019
  65. Jaguszewski M., Osipova J., Ghadri J.R. et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction // Eur. Heart J. 2014. V. 35. № 15. P. 999–1006. https://doi.org/10.1093/eurheartj/eht392
  66. Roncarati R., Viviani Anselmi C., Losi M.A. et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2014. V. 63. № 9. P. 920–927. https://doi.org/10.1016/j.jacc.2013.09.041
  67. Costantino S., Paneni F., Lüscher T.F., Cosentino F. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart // Eur. Heart J. 2016. V. 37. № 6. P. 572–576. https://doi.org/10.1093/eurheartj/ehv599
  68. de Gonzalo-Calvo D., van der Meer R.W., Rijzewijk L.J. et al. Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes // Sci. Rep. 2017. V. 7. № 1. P. 47. https://doi.org/10.1038/s41598-017-00070-6
  69. Li M., Chen X., Chen L. et al. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM // J. Transl. Med. 2018. V. 16. № 1. P. 161. https://doi.org/10.1186/s12967-018-1534-3
  70. Scolari F.L., Faganello L.S., Garbin H.I. et al. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy // Int. J. Cardiol. 2021. V. 327. P. 146–154. https://doi.org/10.1016/j.ijcard.2020.11.004
  71. Calderon-Dominguez M., Belmonte T., Quezada-Feijoo M. et al. Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy // Sci. Rep. 2021. V. 11. № 1. P. 7517. https://doi.org/10.1038/s41598-021-87086-1
  72. Hailu F.T., Karimpour-Fard A., Toni L.S. et al. Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy // Pediatr. Res. 2021. May 19. https://doi.org/10.1038/s41390-021-01548-w
  73. Khudiakov A.A., Panshin D.D., Fomicheva Y.V. et al. Different expressions of pericardial fluid MicroRNAs in patients with arrhythmogenic right ventricular cardiomyopathy and ischemic heart disease undergoing ventricular tachycardia ablation // Front. Cardiovasc. Med. 2021. V. 8. P. 647812. https://doi.org/10.3389/fcvm.2021.647812
  74. Liu Y., Li Y., Li J. et al. Inhibiting miR‑1 attenuates pulmonary arterial hypertension in rats // Mol. Med. Rep. 2021. V. 23(4): 283. https://doi.org/10.3892/mmr.2021.11922
  75. Thottakara T., Lund N., Krämer E. et al. A novel miRNA screen identifies miRNA-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy // Biomolecules. 2021. V. 11. № 11. P. 1718. https://doi.org/10.3390/biom11111718
  76. Chen S., Puthanveetil P., Feng B. et al. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes // J. Cell. Mol. Med. 2014. V. 18. № 3. P. 415–421. https://doi.org/10.1111/jcmm.12218
  77. Fang L., Ellims A.H., Moore X.L. et al. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy // J. Transl. Med. 2015. V. 13. P. 314. https://doi.org/10.1186/s12967-015-0672-0
  78. Renaud L., Harris L.G., Mani S.K. et al. HDACs regulate miR-133a expression in pressure overload-induced cardiac fibrosis // Circ. Heart. Fail. 2015. V. 8. № 6. P. 1094–1104. https://doi.org/10.1161/CIRCHEARTFAILURE.114. 001781
  79. Besler C., Urban D., Watzka S. et al. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy // Eur. J. Heart Fail. 2016. V. 18. № 12. P. 1442–1451. https://doi.org/10.1002/ejhf.579
  80. Huang L., Xi Z., Wang C. et al. Phenanthrene exposure induces cardiac hypertrophy via reducing miR-133a expression by DNA methylation // Sci. Rep. 2016. V. 6. P. 20105. https://doi.org/10.1038/srep20105
  81. Wang Y., Li M., Xu L. et al. Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy // Mol. Med. Rep. 2017. V. 15. № 1. P. 359–365. https://doi.org/10.3892/mmr.2016.5977
  82. Rubiś P., Totoń-Żurańska J., Wiśniowska-Śmiałek S. et al. The relationship between myocardial fibrosis and myocardial microRNAs in dilated cardiomyopathy: A link between mir-133a and cardiovascular events // J. Cell. Mol. Med. 2018. V. 22. № 4. P. 2514–2517. https://doi.org/10.1111/jcmm.13535
  83. Dziewięcka E., Totoń-Żurańska J., Wołkow P. et al. Relations between circulating and myocardial fibrosis-linked microRNAs with left ventricular reverse remodeling in dilated cardiomyopathy // Adv. Clin. Exp. Med. 2020. V. 29. № 3. P. 285–293. https://doi.org/10.17219/acem/115088
  84. Bueno Marinas M., Celeghin R., Cason M. et al. A microRNA expression profile as non-invasive biomarker in a large arrhythmogenic cardiomyopathy cohort // Int. J. Mol. Sci. 2020. V. 21. № 4. P. 1536. https://doi.org/10.3390/ijms21041536
  85. Satoh M., Minami Y., Takahashi Y. et al. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy // J. Card. Fail. 2010. V. 16. № 5. P. 404–410. https://doi.org/10.1016/j.cardfail.2010.01.002
  86. Xue J., Zhou D., Poulsen O. et al. Exploring miRNA-mRNA regulatory network in cardiac pathology in Na+/H+ exchanger isoform 1 transgenic mice // Physiol. Genomics. 2018. V. 50. № 10. P. 846–861. https://doi.org/10.1152/physiolgenomics.00048.2018
  87. Qiang L., Hong L., Ningfu W. et al. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients // Int. J. Cardiol. 2013. V. 168. № 3. P. 2082–2088. https://doi.org/10.1016/j.ijcard.2013.01.160
  88. Matkovich S.J., Hu Y., Eschenbacher W.H. et al. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy // Circ. Res. 2012. V. 111. № 5. P. 521–531. https://doi.org/10.1161/CIRCRESAHA.112.265736
  89. Calore M., Lorenzon A., Vitiello L. et al. A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation // Cardiovasc. Res. 2019. V. 115. № 4. P. 739–751. https://doi.org/10.1093/cvr/cvy253
  90. Zhao L., Li W., Zhao H. Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p // Am. J. Transl. Res. 2020. V. 12. № 3. P. 718–730.
  91. Yang F., Qin Y., Wang Y. et al. LncRNA KCNQ1OT1 mediates pyroptosis in diabetic cardiomyopathy // Cell. Physiol. Biochem. 2018. V. 50. № 4. P. 1230–1244. https://doi.org/10.1159/000494576
  92. Zhao S.F., Ye Y.X., Xu J.D. et al. Long non-coding RNA KCNQ1OT1 increases the expression of PDCD4 by targeting miR-181a-5p, contributing to cardiomyocyte apoptosis in diabetic cardiomyopathy // Acta Diabetol. 2021. V. 58. № 9. P. 1251–1267. https://doi.org/10.1007/s00592-021-01713-x
  93. Duisters R.F., Tijsen A.J., Schroen B. et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling // Circ. Res. 2009. V. 104. № 2. P. 170–178. https://doi.org/10.1161/CIRCRESAHA.108.182535
  94. Gutmann C., Khamina K., Theofilatos K. et al. Association of cardiometabolic microRNAs with COVID-19 severity and mortality // Cardiovasc. Res. 2022. V. 118. № 2. P. 461–474. https://doi.org/10.1093/cvr/cvab338
  95. Kontaraki J.E., Marketou M.E., Kochiadakis G.E. et al. The long non-coding RNAs MHRT, FENDRR and CARMEN, their expression levels in peripheral blood mononuclear cells in patients with essential hypertension and their relation to heart hypertrophy // Clin. Exp. Pharmacol. Physiol. 2018. V. 45. № 11. P. 1213–1217. https://doi.org/10.1111/1440-1681.12997
  96. van Rooij E., Sutherland L.B., Qi X. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA // Science. 2007. V. 316. № 5824. P. 575–579. https://doi.org/10.1126/science.1139089
  97. Wang W., Wu C., Ren L. et al. MiR-30e-5p is sponged by Kcnq1ot1 and represses Angiotensin II-induced hypertrophic phenotypes in cardiomyocytes by targeting ADAM9 // Exp. Cell. Res. 2020. V. 394. № 2. P. 112140. https://doi.org/10.1016/j.yexcr.2020.112140
  98. Jia Y., Duan Y., Liu T. et al. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5 // Cell Death Dis. 2019. V. 10. № 8. P. 573. https://doi.org/10.1038/s41419-019-1811-y
  99. Chen P., Wang R., Yue Q., Hao M. Long non-coding RNA TTN-AS1 promotes cell growth and metastasis in cervical cancer via miR-573/E2F3 // Biochem. Biophys. Res. Commun. 2018. V. 503. № 4. P. 2956–2962. https://doi.org/10.1016/j.bbrc.2018.08.077
  100. Dong M.M., Peng S.J., Yuan Y.N., Luo H.P. LncRNA TTN-AS1 contributes to gastric cancer progression by acting as a competing endogenous RNA of miR-376b-3p // Neoplasma. 2019. V. 66. № 4. P. 564–575. https://doi.org/10.4149/neo_2018_180927N721
  101. Tian C., Yang Y., Ke Y. et al. Integrative analyses of genes associated with right ventricular cardiomyopathy induced by tricuspid regurgitation // Front. Genet. 2021. V. 12. P. 708275. https://doi.org/10.3389/fgene.2021.708275
  102. Jiao M., You H.Z., Yang X.Y. et al. Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy // Sci. Rep. 2018. V. 8. № 1. P. 724. https://doi.org/10.1038/s41598-017-19138-4
  103. Toro R., Blasco-Turrión S., Morales-Ponce F.J. et al. Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy // J. Mol. Med. (Berl.) 2018. V. 96. № 8. P. 845–856. https://doi.org/10.1007/s00109-018-1666-1
  104. Wang J., Jia Z., Zhang C. et al. miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2 // RNA Biol. 2014. V. 11. № 4. P. 339–350. https://doi.org/10.4161/rna.28300
  105. Paul A., Pai P.G., Ariyannur P.S., Joy R.A. Diagnostic accuracy of MicroRNA 208b level with respect to different types of atrial fibrillation // Indian Heart J. 2021. V. 73. № 4. P. 506–510. https://doi.org/10.1016/j.ihj.2021.06.018
  106. Yoneda Z.T., Anderson K.C., Quintana J.A. et al. Early-onset atrial fibrillation and the prevalence of rare variants in cardiomyopathy and arrhythmia genes // JAMA Cardiol. 2021. V. 6. № 12. P. 1371–1379. https://doi.org/10.1001/jamacardio.2021.3370
  107. Cipriani A., Perazzolo Marra M., Bariani R. et al. Differential diagnosis of arrhythmogenic cardiomyopathy: Phenocopies versus disease variants // Minerva Med. 2021. V. 112. № 2. P. 269–280. https://doi.org/10.23736/S0026-4806.20.06782-8
  108. Li M., Wang Y.F., Yang X.C. et al. Circulating long noncoding RNA LIPCAR acts as a novel biomarker in patients with ST-segment elevation myocardial infarction // Med. Sci. Monit. 2018. V. 24. P. 5064–5070. https://doi.org/10.12659/MSM.909348
  109. Wang Y., Jiao J., Wang D. et al. Effects of ticagrelor on proliferation, apoptosis, and inflammatory factors of human aortic vascular smooth muscle cells through lncRNA KCNQ1OT1 // Am. J. Transl. Res. 2021. V. 13. № 12. P. 13462–13470.
  110. Zhang L., Wu Y.J., Zhang S.L. Circulating lncRNA MHRT predicts survival of patients with chronic heart failure // J. Geriatr. Cardiol. 2019. V. 16. № 11. P. 818–821. https://doi.org/10.11909/j.issn.1671-5411.2019.11.006
  111. Xuan L., Sun L., Zhang Y. et al. Circulating long non-coding RNAs NRON and MHRT as novel predictive biomarkers of heart failure // J. Cell. Mol. Med. 2017. V. 21. № 9. P. 1803–1814. https://doi.org/10.1111/jcmm.13101
  112. Zhang J., Gao C., Meng M., Tang H. Long noncoding RNA MHRT protects cardiomyocytes against H2O2-induced apoptosis // Biomol. Ther. (Seoul). 2016. V. 24. № 1. P. 19–24. https://doi.org/10.4062/biomolther.2015.066
  113. Lang M., Ou D., Liu Z. et al. LncRNA MHRT promotes cardiac fibrosis via miR-3185 pathway following myocardial infarction // Int. Heart. J. 2021. V. 62. № 4. P. 891–899. https://doi.org/10.1536/ihj.20-298
  114. Zhou Q., Chen J., Wu D. et al. Differential expression of long non-coding RNAs SRA, HCG22 and MHRT in children with Kawasaki disease // Exp. Ther. Med. 2021. V. 22. № 3. P. 1022. https://doi.org/10.3892/etm.2021.10454
  115. Ma X., Zhang Q., Zhu H. et al. Establishment and analysis of the lncRNA-miRNA-mRNA network based on competitive endogenous RNA identifies functional genes in heart failure // Math. Biosci. Eng. 2021. V. 18. № 4. P. 4011–4026. https://doi.org/10.3934/mbe.2021201
  116. Kang B., Li W., Xi W. et al. Hydrogen sulfide protects cardiomyocytes against apoptosis in ischemia/reperfusion through MiR-1-regulated histone deacetylase 4 pathway // Cell. Physiol. Biochem. 2017. V. 41. № 1. P. 10–21. https://doi.org/10.1159/000455816
  117. Li M., Ding W., Tariq M.A. et al. A circular transcript of ncx1 gene mediates ischemic myocardial injury by targeting miR-133a-3p // Theranostics. 2018. V. 8. № 21. P. 5855–5869. https://doi.org/10.7150/thno.27285
  118. Jiang Y., Du W., Chu Q. et al. Downregulation of long non-coding RNA Kcnq1ot1: An important mechanism of arsenic trioxide-induced long QT syndrome // Cell. Physiol. Biochem. 2018. V. 45. № 1. P. 192–202. https://doi.org/10.1159/000486357
  119. Shirazi-Tehrani E., Firouzabadi N., Tamaddon G. et al. Carvedilol alters circulating MiR-1 and MiR-214 in heart failure // Pharmgenomics. Pers. Med. 2020. V. 13. P. 375–383. https://doi.org/10.2147/PGPM.S263740
  120. Zhuang S., Ma Y., Zeng Y. et al. METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis // Cell. Biol. Toxicol. 2021. Oct 14. https://doi.org/10.1007/s10565-021-09660-7
  121. Lai L., Xu Y., Kang L. et al. LncRNA KCNQ1OT1 contributes to cardiomyocyte apoptosis by targeting FUS in heart failure // Exp. Mol. Pathol. 2020. V. 115. P. 104480.https://doi.org/10.1016/j.yexmp.2020.104480
  122. Durr A.J., Hathaway Q.A., Kunovac A. et al. Manipulation of the MiR-378a/mt-ATP6 regulatory axis rescues ATP synthase in the diabetic heart and offers a novel role for LncRNA Kcnq1ot1 // Am. J. Physiol. Cell. Physiol. 2022. V. 322. № 2. P. C482–C495. https://doi.org/10.1152/ajpcell.00446.2021
  123. Yang F., Qin Y., Lv J. et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy // Cell. Death. Dis. 2018. V. 9. № 10. P. 1000. https://doi.org/10.1038/s41419-018-1029-4
  124. Shen C., Kong B., Liu Y. et al. YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by modulating miR‑384b/CACNA1C axis // Biochem. Biophys. Res. Commun. 2018. V. 505. № 1. P. 134–140. https://doi.org/10.1016/j.bbrc.2018.09.064
  125. Parikh M., Kura B., O’Hara K.A. et al. Cardioprotective effects of dietary flaxseed post-infarction are associated with changes in MicroRNA expression // Biomolecules. 2020. V. 10. № 9. P. 1297. https://doi.org/10.3390/biom10091297
  126. Pan F., Xu X., Zhan Z., Xu Q. 6-Gingerol protects cardiomyocytes against hypoxia-induced injury by regulating the KCNQ1OT1/miR-340-5p/PI3K/AKT pathway // Panminerva Med. 2021. V. 63. № 4. P. 482–490. https://doi.org/10.23736/S0031-0808.20.03956-7
  127. Gao Y., Huang R., Chen R. et al. Ischemic postconditioning altered microRNAs in human valve replacement // J. Surg. Res. 2016. V. 200. № 1. P. 28–35. https://doi.org/10.1016/j.jss.2015.07.010
  128. Liao B., Dong S., Xu Z. et al. LncRNA Kcnq1ot1 renders cardiomyocytes apoptosis in acute myocardial infarction model by up-regulating Tead1 // Life Sci. 2020. V. 256. P. 117811. https://doi.org/10.1016/j.lfs.2020.117811
  129. Lin H., Zhu Y., Zheng C. et al. Antihypertrophic Memory after regression of exercise-induced physiological myocardial hypertrophy is mediated by the long noncoding RNA Mhrt779 // Circulation. 2021. V. 143. № 23. P. 2277–2292. https://doi.org/10.1161/CIRCULATIONAHA.120. 047000
  130. Forini F., Nicolini G., Kusmic C. et al. T3 Critically affects the Mhrt/Brg1 axis to regulate the cardiac MHC switch: Role of an epigenetic cross-talk // Cells. 2020. V. 9. № 10. P. 2155. https://doi.org/10.3390/cells9102155
  131. Nishimura Y., Kondo C., Morikawa Y. et al. Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats // J. Appl. Toxicol. 2015. V. 35. № 2. P. 173–180. https://doi.org/10.1002/jat.3044
  132. Dal-Pra S., Hodgkinson C.P., Mirotsou M. et al. Demethylation of H3K27 is essential for the induction of direct cardiac reprogramming by miR combo // Circ. Res. 2017. V. 120. № 9. P. 1403–1413. https://doi.org/10.1161/CIRCRESAHA.116.308741
  133. Jiang F., Zhou X., Huang J. Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy // PLoS One. 2016. V. 11. № 4. P. e0152767. https://doi.org/10.1371/journal.pone.0152767
  134. Luo Y., Xu Y., Liang C. et al. The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin // Cell. Signal. 2018. V. 43. P. 11–20. https://doi.org/10.1016/j.cellsig.2017.11.007
  135. Xu Y., Luo Y., Liang C., Zhang T. LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis // J. Mol. Cell. Cardiol. 2020. V. 139. P. 47–61. https://doi.org/10.1016/j.yjmcc.2019.12.013
  136. Bian W., Jiang X.X., Wang Z. et al. Comprehensive analysis of the ceRNA network in coronary artery disease // Sci. Rep. 2021. V. 11. № 1. P. 24279. https://doi.org/10.1038/s41598-021-03688-9
  137. Liu Y., Yu B. MicroRNA 186 5p is expressed highly in ethanol induced cardiomyocytes and regulates apoptosis via the target gene XIAP // Mol. Med. Rep. 2019. V. 19. № 4. P. 3179–3189. https://doi.org/10.3892/mmr.2019.9953
  138. Florian A., Patrascu A., Tremmel R. et al. Identification of cardiomyopathy-associated circulating miRNA biomarkers in muscular dystrophy female carriers using a complementary cardiac imaging and plasma profiling approach // Front. Physiol. 2018. V. 9. P. 1770. https://doi.org/10.3389/fphys.2018.01770
  139. Rong J., Pan H., He J. et al. Long non-coding RNA KCNQ1OT1/microRNA-204-5p/LGALS3 axis regulates myocardial ischemia/reperfusion injury in mice // Cell Signal. 2020. V. 66. P. 109441. https://doi.org/10.1016/j.cellsig.2019.109441
  140. Dai W., Chao X., Jiang Z., Zhong G. lncRNA KCNQ1OT1 may function as a competitive endogenous RNA in atrial fibrillation by sponging miR‑223‑3p // Mol. Med. Rep. 2021. V. 24. № 6. P. 870. https://doi.org/10.3892/mmr.2021.12510
  141. Chen Y., Zhang Z., Zhu D. et al. Knockdown of KCNQ1OT1 attenuates cardiac hypertrophy through modulation of the miR-2054/AKT3 axis // J. Thorac. Dis. 2020. V. 12. № 9. P. 4771–4780. https://doi.org/10.21037/jtd-20-203
  142. Li J., Tong Y., Zhou Y. et al. LncRNA KCNQ1OT1 as a miR-26a-5p sponge regulates ATG12-mediated cardiomyocyte autophagy and aggravates myocardial infarction // Int. J. Cardiol. 2021. V. 338. P. 14–23. https://doi.org/10.1016/j.ijcard.2021.05.053
  143. Shen W., Li H., Su H. et al. FTO overexpression inhibits apoptosis of hypoxia/reoxygenation-treated myocardial cells by regulating m6A modification of Mhrt // Mol. Cell. Biochem. 2021. V. 476. № 5. P. 2171–2179. https://doi.org/10.1007/s11010-021-04069-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2.

Download (652KB)
Indexing metadata
3.

Download (300KB)
Indexing metadata

Copyright (c) 2023 А.Н. Кучер, М.С. Назаренко

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».